Prescient Therapeutics Ltd Total Liabilities
Prescient Therapeutics Ltd total liabilities. Based on the latest financial reports, Prescient Therapeutics Ltd (PTX) has total liabilities worth AU$1.51 Million AUD (≈ $1.07 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Prescient Therapeutics Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Prescient Therapeutics Ltd (1989–2025)
Total liabilities of Prescient Therapeutics Ltd from 1989 to 2025. This chart illustrates how Prescient Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data.
Prescient Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Prescient Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chilwa Minerals Ltd
AU:CHW
|
Australia | AU$1.60 Million |
|
SSC Security Services Corp
V:SECU
|
Canada | CA$22.57 Million |
|
LORDS CHLORO ALKALI ORD T (BSE)
NSE:LORDSCHLO
|
India | Rs2.36 Billion |
|
Jorjin Technologies
TWO:4980
|
Taiwan | NT$92.54 Million |
|
Seafresh Industry Public Company Limited
BK:CFRESH
|
Thailand | ฿2.70 Billion |
|
Feerum S.A.
WAR:FEE
|
Poland | zł42.23 Million |
|
Nido Education Ltd
AU:NDO
|
Australia | AU$213.70 Million |
|
Cornerstone OnDemand Inc
F:8CO
|
Germany | €39.72 Million |
Liability Composition Analysis (1989–2025)
This chart breaks down Prescient Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Prescient Therapeutics Ltd total assets.
Liquidity & Leverage Metrics
Prescient Therapeutics Ltd Total Liabilities Ratios Explained
Prescient Therapeutics Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 7.62 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Prescient Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Prescient Therapeutics Ltd (1989–2025)
The table below shows the annual total liabilities of Prescient Therapeutics Ltd from 1989 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$3.17 Million ≈ $2.25 Million |
+36.50% |
| 2024-06-30 | AU$2.33 Million ≈ $1.65 Million |
+14.40% |
| 2023-06-30 | AU$2.03 Million ≈ $1.44 Million |
+137.49% |
| 2022-06-30 | AU$856.01K ≈ $605.68K |
+58.62% |
| 2021-06-30 | AU$539.68K ≈ $381.86K |
-38.95% |
| 2020-06-30 | AU$883.95K ≈ $625.45K |
+28.89% |
| 2019-06-30 | AU$685.79K ≈ $485.24K |
+24.34% |
| 2018-06-30 | AU$551.56K ≈ $390.26K |
+23.98% |
| 2017-06-30 | AU$444.89K ≈ $314.79K |
-45.91% |
| 2016-06-30 | AU$822.55K ≈ $582.01K |
+86.47% |
| 2015-06-30 | AU$441.13K ≈ $312.13K |
+74.43% |
| 2014-06-30 | AU$252.89K ≈ $178.94K |
-86.32% |
| 2012-06-30 | AU$1.85 Million ≈ $1.31 Million |
+20.53% |
| 2011-06-30 | AU$1.53 Million ≈ $1.09 Million |
+19.02% |
| 2010-06-30 | AU$1.29 Million ≈ $911.86K |
-27.85% |
| 2009-06-30 | AU$1.79 Million ≈ $1.26 Million |
+6.48% |
| 2008-06-30 | AU$1.68 Million ≈ $1.19 Million |
+13.62% |
| 2007-06-30 | AU$1.48 Million ≈ $1.04 Million |
-12.15% |
| 2006-06-30 | AU$1.68 Million ≈ $1.19 Million |
+24.23% |
| 2005-06-30 | AU$1.35 Million ≈ $957.17K |
+164.83% |
| 2004-06-30 | AU$510.81K ≈ $361.43K |
-24.88% |
| 2003-06-30 | AU$680.00K ≈ $481.14K |
+51.64% |
| 2002-06-30 | AU$448.42K ≈ $317.29K |
-32.84% |
| 2001-06-30 | AU$667.73K ≈ $472.46K |
+520.49% |
| 2000-06-30 | AU$107.61K ≈ $76.14K |
-10.10% |
| 1999-06-30 | AU$119.70K ≈ $84.70K |
+93.13% |
| 1998-06-30 | AU$61.98K ≈ $43.85K |
-54.90% |
| 1997-06-30 | AU$137.43K ≈ $97.24K |
+109.17% |
| 1996-06-30 | AU$65.70K ≈ $46.49K |
-97.24% |
| 1995-06-30 | AU$2.38 Million ≈ $1.69 Million |
-57.18% |
| 1994-06-30 | AU$5.57 Million ≈ $3.94 Million |
+11.23% |
| 1993-06-30 | AU$5.00 Million ≈ $3.54 Million |
-11.84% |
| 1992-06-30 | AU$5.67 Million ≈ $4.02 Million |
+4.61% |
| 1991-06-30 | AU$5.42 Million ≈ $3.84 Million |
+0.67% |
| 1990-06-30 | AU$5.39 Million ≈ $3.81 Million |
-1.86% |
| 1989-06-30 | AU$5.49 Million ≈ $3.89 Million |
-- |
About Prescient Therapeutics Ltd
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to… Read more